{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:58Z","timestamp":1792114138481,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In patients with cardiovascular (CV) comorbidities that necessitate antiplatelet therapy (APT), its optimal management during chemotherapy-induced thrombocytopenia remains elusive, as the risk of bleeding has to be balanced against the risk of CV events. The purpose of this study was to assess the risk for bleeding with APT during thrombocytopenia in patients with multiple myeloma undergoing high-dose chemotherapy and subsequent autologous stem-cell transplantation (ASCT) with and without acetylsalicylic acid (ASA) as comedication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We assessed patients who underwent ASCT at the Heidelberg University Hospital between 2011 and 2020 for bleeding events, management strategies for ASA intake during thrombocytopenia, transfusion requirements, and the occurrence of CV events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 57\/1,113 patients who continued ASA until at least 1 day after ASCT; thus, a continuous platelet inhibition during thrombocytopenia was assumed. Most of the patients (41\/57) continued ASA until they had a platelet count of 20\u201350\/nl. This range reflects the kinetics of thrombocytopenia and nondaily measurements of platelets during ASCT. A tendency toward a higher risk for bleeding events in the ASA group was demonstrated (1.9% (control group) <jats:italic>vs<\/jats:italic>. 5.3% (ASA), p = 0.082). The risk factors for bleeding in multivariate analysis were the duration of thrombocytopenia &amp;lt; 50\/nl, a history of gastrointestinal bleeding, and diarrhea. The factors predicting the duration of thrombocytopenia were age &amp;gt;60 years, a hematopoietic stem-cell transplantation comorbidity index \u22653, and an impaired bone marrow reserve at admission. CV events occurred in three patients; none of them took ASA or had an indication for APT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The intake of ASA until thrombocytopenia with a platelet count of 20\u201350\/nl appears safe, although an elevated risk cannot be excluded. If ASA is indicated for the secondary prevention of CV events, the evaluation of risk factors for bleeding and a prolonged time of thrombocytopenia before conditioning is crucial to adapt the strategy for ASA intake during thrombocytopenia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1168120","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:19:40Z","timestamp":1682572780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma"],"prefix":"10.3389","volume":"13","author":[{"given":"Nina Rosa","family":"Neuendorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boryana","family":"Boshikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Frankenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.03.004","article-title":"Prevalence of cardiovascular disease in patients with potentially curable malignancies: a national registry dataset analysis","volume":"4","author":"Battisti","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26872","article-title":"Prevalence of cardiovascular risk factors and diseases in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation","volume":"10","author":"Backs","year":"2019","journal-title":"Oncotarget"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.07.033","article-title":"Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia","volume":"122","author":"Iliescu","year":"2018","journal-title":"Am J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/1076029608319945","article-title":"Prothrombotic and hemorrhagic effects of aspirin","volume":"15","author":"Aguejouf","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028321","article-title":"Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study","volume":"136","author":"Sundstrom","year":"2017","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000145171.89690.B4","article-title":"Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes","volume":"110","author":"Collet","year":"2004","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2796.2005.01477.x","article-title":"Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis","volume":"257","author":"Burger","year":"2005","journal-title":"J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.22.2472","article-title":"Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction","volume":"164","author":"Fischer","year":"2004","journal-title":"Arch Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.11.041","article-title":"Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis","volume":"45","author":"Ferrari","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.813667","article-title":"Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents","volume":"119","author":"Eisenberg","year":"2009","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820d62b5","article-title":"Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study","volume":"76","author":"Garc\u00eda Rodr\u00edguez","year":"2011","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-757930","article-title":"Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial","volume":"130","author":"Uhl","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-019-01484-0","article-title":"Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the management of aspirin-induced gastrointestinal complications (MAGIC) study","volume":"35","author":"Uchiyama","year":"2020","journal-title":"Heart Vessels"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000136","article-title":"How well do platelets prevent bleeding","volume":"2020","author":"Triulzi","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1053\/tmrv.2002.29403","article-title":"Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? a reevaluation of prophylactic platelet transfusions","volume":"16","author":"Friedmann","year":"2002","journal-title":"Transfus Med Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.5.1105.1105","article-title":"Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement","volume":"66","author":"Hanson","year":"1985","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705246","article-title":"A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation","volume":"37","author":"Wandt","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60689-8","article-title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study","volume":"380","author":"Wandt","year":"2012","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cgh.2016.07.017","article-title":"No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents","volume":"15","author":"Zakko","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","article-title":"Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial","volume":"152","author":"Sung","year":"2010","journal-title":"Ann Intern Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03634.x","article-title":"A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia","volume":"52","author":"Webert","year":"2012","journal-title":"Transfusion"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"HemaSphere"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.05.008","article-title":"Effect of preprocedural thrombocytopenia on prognosis after percutaneous coronary intervention","volume":"91","author":"Raphael","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2063-18","article-title":"Effects of baseline thrombocytopenia on in-hospital outcomes in patients undergoing elective percutaneous coronary intervention","volume":"58","author":"Shiraishi","year":"2019","journal-title":"Intern Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22434","article-title":"Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes","volume":"109","author":"Sarkiss","year":"2007","journal-title":"Cancer"},{"key":"B30","article-title":"Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia","volume":"37","author":"Yusuf","year":"2010","journal-title":"Tex Heart Inst J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04641.x","article-title":"Reversal of the anti-platelet effects of aspirin and clopidogrel","volume":"10","author":"Li","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04699.x","article-title":"Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study","volume":"10","author":"Thiele","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13962","article-title":"Preoperative platelet transfusions to reverse antiplatelet therapy for urgent non-cardiac surgery: an observational cohort study","volume":"16","author":"Baschin","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04392.x","article-title":"Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study","volume":"9","author":"Pruller","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2019.01.002","article-title":"Role of platelet transfusion in the reversal of anti-platelet therapy","volume":"33","author":"Nagalla","year":"2019","journal-title":"Transfus Med Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000118288.04483.02","article-title":"Antiplatelet drug discontinuation is a risk factor for ischemic stroke","volume":"62","author":"Sibon","year":"2004","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0132-6","article-title":"Bloodless tandem autologous transplant in jehovah's witness patients","volume":"53","author":"Khan","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.04.023","article-title":"Thrombotic and hemorrhagic complications in children and young adult recipients of hematopoietic stem cell transplant (HSCT)","volume":"167","author":"Kaur","year":"2018","journal-title":"Thromb Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.118075","article-title":"Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis","volume":"100","author":"Stanworth","year":"2015","journal-title":"Haematologica"},{"key":"B40","article-title":"The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia","volume":"91","author":"Webert","year":"2006","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1168120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:19:44Z","timestamp":1682572784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1168120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":40,"alternative-id":["10.3389\/fonc.2023.1168120"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1168120","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"article-number":"1168120"}}